Roche Experimenting With New Pricing Models In Oncology

Cancer drug prices are unsustainable and creative approaches are needed, Roche’s COO Daniel O’Day says. The firm’s moves into emerging markets are a lab for new methods, though the real test will come as the more expensive drugs are used in combination.

The time has come for Roche to revise its approach to oncology drug pricing, Pharmaceuticals Division Chief Operating Officer Daniel O’Day stated at an analyst briefing held at the American Society for Clinical Oncology annual meeting June 2. Payment will need to move away from volume, especially as expensive combinations become more widespread in treating cancer, O’Day suggested. “The days of looking at per-milligram price, I think for us in many countries, and certainly when we look at the next three years, it’s unsustainable,” he acknowledged. “It's unsustainable to suggest that we're just going to simply add another therapy at $8,000 to $10,000 a month on top of each other and expect constrained health care systems to be able to pay for that. So we have to be a bit more creative about it,” he said.

It’s a change that’s been a long time coming. As expensive drugs like Avastin (bevacizumab) move into new settings with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.